Source: centralcharts

Press Release: Absci : Absci to Participate in the TD Cowen 45th Annual Health Care Conference

VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today

Read full article »

Absci's Competitors | Absci's News | Absci's Financials

Followers on Owler

1,004

Annual Revenue

$100K-5.0M

Employees

100-250

Founder & CEO

Sean McClain

CEO Approval Rating

90/100

Absci is a Washington-based generative AI platform that offers solutions including drug discovery, screening, and synthetic biology research for the pharmaceutical sector.